ABVD


Also found in: Acronyms, Wikipedia.

ABVD

Abbreviation for a chemotherapy regimen of Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine; used in the treatment of Hodgkin lymphoma.

ABVD

an anticancer drug combination of DOXOrubicin, bleomycin, vinBLASTine, and dacarbazine.

ABVD

A “salvage” chemotherapy regimen—doxorubicin, bleomycin, vinblastine, dacarbazine—used for patients who have had disease (e.g., lymphoma) relapse after primary radiotherapy or chemotherapy; 6–8 months of ABVD is as effective as 12 months of MOPP-ABVD; both are more effective than MOPP alone.

ABVD

Doxorubicin, bleomycin, vinblastine, dacarbazine Oncology A 'salvage' chemotherapy regimen used for Pts who have had disease–eg, lymphoma relapse after 1º RT or chemotherapy. See CHOP, MOPP, Salvage chemotherapy.
References in periodicals archive ?
When analyzing results specifically for high-risk patients, who may carry a poorer prognosis, the findings were generally similar to the primary analysis, with higher OS rates observed in the ABVD treatment arm group (92%) when compared to the ABVD plus RT group (81%).
Continued follow-up will also be of interest regarding secondary malignancies and other late complication for those treated with ABVD versus BEACOPP and for those receiving 20 Gy versus 30 Gy of IFRT.
The ABVD regimen is a non-alkylating regimen that is less gonadotoxic compared to regimens including alkylating agents.
Previous research of the HD8 trial by the German Hodgkin Study Group demonstrated that the standard treatment for early, unfavorable Hodgkin lymphoma is combination chemotherapy along with involved field radiation therapy (IF-RT) - four cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) followed by IF-RT, a treatment in which radiation is delivered only to areas of the body affected by the lymphoma.
For over 30 years, the standard of care for front-line HL has been a chemotherapy regimen called ABVD that has demonstrated a complete remission rate of 70 to 80 percent and is associated with considerable life-threatening toxicities.
The patient developed dizziness, limb weakness, involuntary contractions of the hands and feet, incontinence, headache, fever, nausea, and vomiting following the first cycle of treatment with the ABVD protocol (adriamycin 25 mg [m.
Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD.
I began chemotherapy with ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) on November 17, 2000.
Patients received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), MOPP/ABV (mechlorethamine, vincristine, procarbazine, and prednisone), or other ABVD-like chemotherapy.
Complete remission was achieved after six cycles of chemotherapy with ABVD (Adriamycin: 25 mg/[m.
The contraindication for the concomitant use of ADCETRIS and bleomycin is based on data suggesting an increased risk of pulmonary toxicity relative to ABVD alone that was identified in our phase I clinical trial in patients with newly diagnosed advanced Hodgkin lymphoma.